Positive Phase 1a Results for TTX-MC138: 64% Stable Disease, Advances to Phase 2a
RNAZ is trading near its 52-week low of $5.01 (17% below the low).
Summary
TransCode Therapeutics reported successful Phase 1a clinical trial results for its lead drug candidate, TTX-MC138, showing no dose-limiting toxicities and 64% of evaluable patients achieving stable disease. The company will now advance TTX-MC138 into a Phase 2a trial for colorectal cancer. This positive clinical development provides a much-needed boost for the micro-cap biotech, which has recently faced significant financial challenges, including multiple 'going concern' warnings, a short cash runway, and a Nasdaq deficiency notice. The news, also confirmed by an 8-K filing today, could materially impact investor sentiment and the company's ability to secure future funding.
At the time of this announcement, RNAZ was trading at $4.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5M. The 52-week trading range was $5.01 to $20.99. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.